Perceptive and Trialzen Target Clinical Trial Waste with New Alliance

NOTTINGHAM, England and LASNE, Belgium – April 27, 2026 – Perceptive eClinical, a long-standing leader in clinical trial technology, today announced a strategic alliance with forecasting specialist Trialzen to launch a new service aimed at tackling one of the pharmaceutical industry's most persistent and costly problems: wasted clinical trial supply.

The new venture, Perceptive Clinical Intelligence, formalizes Perceptive’s deep-seated expertise into a technology-enabled consultancy. By integrating Trialzen's advanced analytics and simulation engine into its own platform, Perceptive aims to provide pharmaceutical sponsors with a unified solution to design, stress-test, and manage their complex supply chains, moving beyond reactive fixes to proactive, data-driven strategy.

A Multi-Billion Dollar Problem

The scale of inefficiency in clinical trial supply is staggering. Industry benchmarks, cited in the announcement and supported by independent analysis, suggest that approximately 50% of all Clinical Finished Goods (CFG) manufactured for trials are never administered to a patient. This represents hundreds of millions of dollars in wasted drug supply annually, inflating R&D budgets and diverting resources that could be used for further innovation.

The financial impact is compounded by operational delays. The clinical trial supply and logistics market, valued at over $4.2 billion in 2024 and projected to exceed $6.7 billion by 2030, is under immense pressure. Inefficiencies can lead to study delays costing anywhere from $600,000 to $8 million per day. However, the consequences extend far beyond the balance sheet.

"While supply discussions often focus on stock levels and overage, the real risk is patient impact," said Malcolm Morrissey, Head of the new Perceptive Clinical Intelligence service. "Supply availability determines whether visits happen, treatment is delivered on time, and sites can operate with confidence. Effective supply management means looking beyond IP numbers to understand patient continuity and visit level risk across the entire trial."

The Hybrid Solution: Expertise Meets Analytics

Perceptive Clinical Intelligence is positioned as a hybrid solution, blending human experience with powerful technology. The consultancy is built on Perceptive's 30 years of experience in randomization and trial supply management (RTSM), which has supported over 500 regulatory approvals and three million patients worldwide. This deep institutional knowledge is now being paired with Trialzen’s Forecast & Planning Solution (FPS), a purpose-built SaaS platform designed by clinical supply experts.

This technology enables sponsors to model and simulate countless scenarios, optimizing everything from packaging and labeling to production schedules and depot shipments. It replaces the traditional reliance on spreadsheets and intuition with mathematical optimization and predictive analytics. The goal is to create more resilient and efficient supply chains from the very beginning of a trial.

Reflecting on the collaboration's purpose, Cedric Druck, CEO and Co-Founder of Trialzen, highlighted the historical disconnect in the industry. "Trialzen was built by clinical supply experts who spent years watching planning decisions get made on spreadsheets and gut feel, then handed off to execution systems with no feedback loop," he commented. "This collaboration with Perceptive closes that gap. By integrating our forecasting and simulation capabilities directly with their IRT platform, we enable sponsors to move from scenario planning to operational action in a single environment, with full transparency at every step."

A Unified Platform for a Fragmented Process

A core tenet of the alliance is the creation of a single, connected environment for planning and execution. The integration of Trialzen’s calculation engine into Perceptive’s next-generation platform, Clinphone Pro, is central to this vision. This allows strategic forecasting and day-to-day operational management to coexist, providing a continuous feedback loop that enables smarter and more agile decision-making.

This unified approach is designed to give sponsors greater confidence, particularly in complex and high-risk trials. The consultancy has a strong focus on oncology, where global studies, intricate dosing regimens, and multi-layered supply chains amplify planning challenges. The service also extends to other complex areas like endocrinology, infectious diseases, and emerging fields such as precision medicine, nuclear medicine, and cell and gene therapies—areas where supply chain failures can have devastating consequences.

"Together, Perceptive and Trialzen are working toward a unified way of operating, where strategic decisions and day-to-day execution come together, enabling greater visibility, smarter scenarios, and more confident supply decisions from manufacturing through to patient dosing," said Tony Street, Senior Vice President of Strategy at Trialzen.

Clients are promised tangible benefits, including faster study start-up, smoother mid-study amendments, and higher-quality supply decisions backed by expert oversight and quantitative data. Both companies point to a track record of success in prior engagements, citing real-world savings exceeding $1 million and significant reductions in drug overage for sponsors.

A Strategic Evolution in a Complex Market

The launch of Perceptive Clinical Intelligence marks a significant strategic pivot for Perceptive eClinical. It represents a deliberate evolution from a premier provider of IRT and eClinical software to a more comprehensive, consultative partner. This move leverages the company’s 2025 recognition as a Leader in Everest Group's PEAK Matrix® for RTSM Solutions, building on a reputation for innovation and delivery excellence.

"Setting up Perceptive Clinical Intelligence reflects the next step in Perceptive's evolution, combining deep clinical supply and randomization expertise with data–driven technology to enable smarter supply planning, and increased supply confidence, and continuity across the trial lifecycle," stated Shaun Hopgood, Chief Operating Officer at Perceptive eClinical.

This strategic shift acknowledges a fundamental truth in the modern clinical landscape: as trials become more global, patient-centric, and scientifically complex, technology alone is not enough. The alliance between Perceptive and Trialzen suggests a future where the most effective solutions will be those that seamlessly combine advanced analytical power with decades of hard-won human experience, ensuring that as medicine becomes more precise, so too does the process of delivering it to patients.